A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found no clinically meaningful differences, plus tbo-filgrastim saved money.
A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found that there were no clinically meaningful differences.
The paper, by researchers from the Texas Transplant Institute, was published in Biology of Blood and Marrow Transplantation.
The researchers studied patients diagnosed with lymphoma or plasma cell disorders who were undergoing granulocyte colon-stimulating factor mobilization. The primary outcome was total collected CD34(+) cells/kg.
Secondary engraftment endpoints of the study were time to neutrophil and events of febrile neutropenia. There were no statistically significant differences in these endpoints.
A total of 185 patients were included in the analysis, and the researchers found that patients receiving filgrastim collected a median of 5.56 × 10(6) CD34(+) cells/kg, compared with a median of 5.85 × 10(6) CD34(+) cells/kg in the tbo-filgrastim group.
Not only were there no statistically meaningful differences in the endpoints, such as events of febrile neutropenia and length of stay, but tbo-filgrastim was associated with savings of $1406 per patient based on the average wholesale price of the treatment.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More